Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words '5-DAY CONTINUOUS INFUSION' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 28 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Erdlenbruch, B; Pekrun, A; Roth, C; Grunewald, RW; Kern, W; Lakomek, M
      Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions

      PEDIATRIC NEPHROLOGY
    2. Erdlenbruch, B; Nier, M; Kern, W; Hiddemann, W; Pekrun, A; Lakomek, M
      Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatricpatients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    3. Ekborn, A; Laurell, G; Andersson, A; Wallin, I; Eksborg, S; Ehrsson, H
      Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig

      HEARING RESEARCH
    4. Kern, W; Braess, J; Kaufmann, CC; Wilde, S; Schleyer, B; Hiddemann, W
      Microalbuminuria during cisplatin therapy: Relation with pharmacokinetics and implications for nephroprotection

      ANTICANCER RESEARCH
    5. Mandell, LR; Kadota, R; Freeman, C; Douglass, EC; Fontanesi, J; Cohen, ME; Kovnar, E; Burger, P; Sanford, RA; Kepner, J; Friedman, H; Kun, LE
      There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results ofa pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    6. SHIMIZU Y; AKIYAMA F; UMEZAWA S; ISHIYA T; UTSUGI K; HASUMI K
      COMBINATION OF CONSECUTIVE LOW-DOSE CISPLATIN WITH BLEOMYCIN, VINCRISTINE, AND MITOMYCIN FOR RECURRENT CERVICAL-CARCINOMA

      Journal of clinical oncology
    7. HON YY; EVANS WE
      MAKING TDM WORK TO OPTIMIZE CANCER-CHEMOTHERAPY - A MULTIDISCIPLINARYTEAM-APPROACH

      Clinical chemistry
    8. SHIMIZU Y
      PHARMACOKINETICS OF CONSECUTIVE LOW-DOSE CISPLATIN

      Oncology Reports
    9. SELVARATNAM G; PHILIPS RH; MOHAMED AK; RADZI A
      ADVERSE-EFFECTS OF CYTOTOXICS PLATINUM AGENTS

      Adverse drug reactions and toxicological reviews
    10. LOKICH J; ANDERSON N
      DOSE INTENSITY FOR BOLUS VERSUS INFUSION CHEMOTHERAPY ADMINISTRATION - REVIEW OF THE LITERATURE FOR 27 ANTINEOPLASTIC AGENTS

      Annals of oncology
    11. LIVINGSTON RB; ELLIS GK; GRALOW JR; WILLIAMS MA; WHITE R; MCGUIRT C; ADAMKIEWICZ BB; LONG CA
      DOSE-INTENSIVE VINORELBINE WITH CONCURRENT GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT IN PACLITAXEL-REFRACTORY METASTATIC BREAST-CANCER

      Journal of clinical oncology
    12. NAGAI N; OGATA H
      QUANTITATIVE RELATIONSHIP BETWEEN PHARMACOKINETICS OF UNCHANGED CISPLATIN AND NEPHROTOXICITY IN RATS - IMPORTANCE OF AREA UNDER THE CONCENTRATION-TIME CURVE (AUC) AS THE MAJOR TOXICODYNAMIC DETERMINANT IN-VIVO

      Cancer chemotherapy and pharmacology
    13. MORI K; OHNISHI T; YOKOYAMA K; TOMINAGA K
      A PHASE-I STUDY OF IRINOTECAN AND INFUSIONAL CISPLATIN FOR ADVANCED NON-SMALL-CELL LUNG-CANCER

      Cancer chemotherapy and pharmacology
    14. CEMAZAR M; SERSA G; AUERSPERG M
      ANTITUMOR EFFECTIVENESS OF BOLUS VERSUS SPLIT-DOSE VINBLASTINE TREATMENT IN EAT TUMORS IN MICE

      Anticancer research
    15. NAGAI N; KINOSHITA M; OGATA H; TSUJINO O; WADA Y; SOMEYA K; OHNO T; MASUHARA K; TANAKA Y; KATO K; NAGAI H; YOKOYAMA A; KURITA Y
      RELATIONSHIP BETWEEN PHARMACOKINETICS OF UNCHANGED CISPLATIN AND NEPHROTOXICITY AFTER INTRAVENOUS INFUSIONS OF CISPLATIN TO CANCER-PATIENTS

      Cancer chemotherapy and pharmacology
    16. MURREN JR; DURIVAGE HJ; BUZAID AC; REISS M; FLYNN SD; CARTER D; HAIT WN
      TRIFLUOPERAZINE AS A MODULATOR OF MULTIDRUG-RESISTANCE IN REFRACTORY BREAST-CANCER

      Cancer chemotherapy and pharmacology
    17. BONI C; MORETTI G; SAVOLDI L; ARMAROLI L; BARBIERI W; BISAGNI G; CAROGGIO A; LOTTI C; PEDRONI C; MANENTI AL; RONDINI E; SASSI M; ZADRO A
      NEOADJUVANT CHEMOTHERAPY WITH CONTINUOUS-INFUSION OF CISPLATIN AND FLUOROURACIL IN STAGE II-IV, M0 SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

      Tumori
    18. VANWARMERDAM LJC; VANDENBEMT BJF; HUININK WWT; MAES RAA; BEIJNEN JH
      DOSE INDIVIDUALIZATION IN CANCER-CHEMOTHERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS

      Cancer research, therapy & control
    19. SELLA A; AGGARWAL BB; KILBOURN RG; BUI CA; ZUKIWSKI AA; LOGOTHETIS CJ
      PHASE-I STUDY OF TUMOR NECROSIS ACTINOMYCIN-D IN PATIENTS WITH INDEPENDENT PROSTATE-CANCER

      Cancer biotherapy
    20. LANGER CJ; CATALANO R; WEINER LM; SCHER R; BAGCHI P; SAREN B; COMIS RL
      PHASE-II EVALUATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) IN ADVANCED, MEASURABLE BREAST-CARCINOMA

      Cancer investigation
    21. MELI M; PALMERI S; LEONARDI V; DANOVA M; FAILLA G; RUSSO A; BRUGNATELLI S; FERRARA P; BENAZZO M; RAUSA L
      A SHORT-TERM INFUSION REGIMEN OF CISPLATIN, 5-FLUOROURACIL AND L-FOLINIC ACID IN ADVANCED HEAD AND NECK-CARCINOMA

      Oncology Reports
    22. TOUSSAINT C; IZZO J; SPIELMANN M; MERLE S; MAYLEVIN F; ARMAND JP; LACOMBE D; TURSZ T; SUNDERLAND M; CHABOT GG; CVITKOVIC E
      PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/

      Journal of clinical oncology
    23. THIBERVILLE L; COMPAGNON P; MOORE N; BASTIAN G; RICHARD MO; HELLOT MF; VINCENT C; KANNASS MM; DOMINIQUE S; THUILLEZ C; NOUVET G
      PLASMA 5-FLUOROURACIL AND ALPHA-FLUORO-BETA-ALANIN ACCUMULATION IN LUNG-CANCER PATIENTS TREATED WITH CONTINUOUS-INFUSION OF CISPLATIN AND 5-FLUOROURACIL

      Cancer chemotherapy and pharmacology
    24. EGORIN MJ; REYNO LM; CANETTA RM; JODRELL DI; SWENERTON KD; PATER JL; BURROUGHS JN; NOVAK MJ; SRIDHARA R
      MODELING TOXICITY AND RESPONSE IN CARBOPLATIN-BASED COMBINATION CHEMOTHERAPY

      Seminars in oncology
    25. DELAFLORWEISS E; UZIELY B; MUGGIA FM
      PROTRACTED DRUG INFUSIONS IN CANCER-TREATMENT - AN APPRAISAL OF 5-FLUOROURACIL, DOXORUBICIN, AND PLATINUMS

      Annals of oncology
    26. SAITO H; SHIMOKATA K; YAMAMOTO M; SAKA H; SAKAI S; SAITO H
      PHASE-II STUDY OF A 72-H CONCURRENT CONTINUOUS INFUSION OF CISPLATIN AND ETOPOSIDE IN ADVANCED NON-SMALL-CELL LUNG-CANCER

      Cancer chemotherapy and pharmacology
    27. KOBAYASHI K; JODRELL DI; RATAIN MJ
      PHARMACODYNAMIC-PHARMACOKINETIC RELATIONSHIPS AND THERAPEUTIC DRUG-MONITORING

      Cancer surveys
    28. DESOIZE B
      TO WHICH CRITERION SHOULD THE DOSE OF ANTICANCER DRUG BE ADAPTED

      Bulletin du cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 15:39:05